Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

Market Cap	61.41B
Revenue (ttm)	30.70B
Net Income (ttm)	4.94B
Shares Out	41.63M
EPS (ttm)	118.71
PE Ratio	12.43
Forward PE	11.36
Dividend	50.00 (3.39%)
Ex-Dividend Date	Mar 28, 2025

Volume	180,200
Average Volume	263,810
Open	1,445.00
Previous Close	1,475.00
Day's Range	1,425.00 - 1,449.00
52-Week Range	970.00 - 1,897.00
Beta	-0.14
RSI	40.71
Earnings Date	May 8, 2025

About TYO:2395

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological ...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1957
• Employees: 1,341
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 2395

Financial Performance

In 2023, TYO:2395's revenue was 26.45 billion, an increase of 5.42% compared to the previous year's 25.09 billion. Earnings were 5.53 billion, a decrease of -8.73%.